Skip to main content

CORRECTION article

Front. Genet., 25 January 2023
Sec. Cancer Genetics and Oncogenomics
Volume 14 - 2023 | https://doi.org/10.3389/fgene.2023.1146199

Corrigendum: A Novel transcription factor-based signature to predict prognosis and therapeutic response of hepatocellular carcinoma

This article is a correction to:

  1. A novel transcription factor-based signature to predict prognosis and therapeutic response of hepatocellular carcinoma

    1. Read original article
Yanbing Yang&#x;Yanbing Yang1†Xuenian Ye&#x;Xuenian Ye2†Haibin ZhangHaibin Zhang2Zhaowang LinZhaowang Lin1Min FangMin Fang1Jian WangJian Wang1Yuyan YuYuyan Yu1Xuwen HuaXuwen Hua1Hongxuan HuangHongxuan Huang2Weifeng XuWeifeng Xu3Ling Liu Ling Liu4*Zhan Lin Zhan Lin1*
  • 1Department of Radiology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China
  • 2Department of Orthopedics, Dongguan People’s Hospital, Dongguan, China
  • 3Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
  • 4Department of Radiology, The First Affiliated Hospital of Dali University, Dali, China

A Corrigendum on
A Novel transcription factor-based signature to predict prognosis and therapeutic response of hepatocellular carcinoma

by Yang Y, Ye X, Zhang H, Lin Z, Fang M, Wang J, Yu Y, Hua X, Huang H, Xu W, Liu L and Lin Z (2023). Front. Genet. 13:1068837. doi: 10.3389/fgene.2022.1068837

In the original article, there was a mistake in the Funding statement as published. The correct grant number for the Startup Fund for Scientific Research of Fujian Medical University is 2018QH1202. Corrected funding statement is given below:

“This work was supported by the Scientific Research Project for the Middle-aged and Youths of Fuzhou Health Department (grant number: 2019-S-wq9) and the Startup Fund for Scientific Research of Fujian Medical University (grant number: 2018QH1202).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: transcription factor, high mobility group AT-hook protein 1, MAF BZIP transcription factor G, prognosis, therapeutic response, hepatocellular carcinoma

Citation: Yang Y, Ye X, Zhang H, Lin Z, Fang M, Wang J, Yu Y, Hua X, Huang H, Xu W, Liu L and Lin Z (2023) Corrigendum: A Novel transcription factor-based signature to predict prognosis and therapeutic response of hepatocellular carcinoma. Front. Genet. 14:1146199. doi: 10.3389/fgene.2023.1146199

Received: 17 January 2023; Accepted: 18 January 2023;
Published: 25 January 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Yang, Ye, Zhang, Lin, Fang, Wang, Yu, Hua, Huang, Xu, Liu and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ling Liu, anddymar@sina.com; Zhan Lin, linzhann977@163.com

†These authors contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.